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license (http://creativeOwing to its lipophilic nature, it preferentially enters the brain, where it is cleaved into active galant-
amine. Gln-1062 is expected to have fewer peripheral side effects than other cholinesterase inhibitors,
with improved effectiveness.
Methods: This was a double-blind, comparator and placebo-controlled, sequential cohort, single
ascending dose study in 58 healthy subjects with Gln-1062 in doses of 5.5, 11, 22, 33, and 44 mg,
compared with oral galantamine 16 mg and donepezil 10 mg. Safety, tolerability, pharmacokinetics,
and pharmacodynamics were assessed.
Results: Gln-1062 doses up to 33 mg were well tolerated and induced a dose-dependent increase in
the plasma concentrations of Gln-1062 and galantamine. Gln-1062 had a dose-dependent positive ef-
fect on verbal memory and attention, mainly in the first hours after drug administration.
Discussion: Gln-1062 was better tolerated than galantamine in doses with the same molarity and led
to improved effects in cognitive tests. This is most likely caused by the more favorable distribution
ratio between peripheral and central cholinesterase inhibition. These results give reason for further
exploration of this compound.
 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: Pharmacology; Galantamine; Donepezil; Side effects; Alzheimer’s disease1. Introduction
Alzheimer’s disease (AD) is the most common form of
dementia. Its pathogenesis involves the progressive develop-
ment of amyloid plaques and tangles, loss of cholinergic
neurons, and cholinergic deficiency. Recent trials with
disease-modifying compounds, such as gamma secretase in-
hibitors and monoclonal antibodies against amyloid b, have
had negative results [1–3]. Post hoc analysis of trial data of
studies with solanezumab in patients with mild AD and there employees of Neurodyn Inc and Galantos Pharma,
authors report no conflicts of interest.
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he Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).first results of trials with aducanumab in patients with mild
or prodromal AD seem to underline the idea that disease
modification might only be useful in earlier stages of the
disease [4,5]. All trials in patients with moderate or severe
AD with disease-modifying compounds have been negative
so far. The first registered treatment in line for the symptoms
of mild-to-moderate AD are cholinesterase inhibitors
(ChEIs). Although not curative, ChEIs can reduce symptoms
for 6–36 months [6]. However, this positive effect is only
seen in 14%–36% of patients [7–11]. Administration of
higher doses, for example, 24 mg of galantamine or 23 mg
of donepezil, leads to an increase in peripheral side
effects, such as nausea, vomiting, and diarrhea, which
overshadows a possible positive effect on cognition and
functioning in daily life [12,13]. As disease modificationimer’s Association. This is an open access article under the CC BY-NC-ND
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AD, it is worthwhile to optimize the available symptomatic
drugs. Therefore, Gln-1062 (Memogain) was developed as a
modification of galantamine having much higher lipophilic-
ity and hence higher preference for the brain than the parent
drug. Gln-1062 was designed as an inactive prodrug (in casu
a benzoic ester) of galantamine that, after entering the brain,
is cleaved into active galantamine by a carboxy-esterase.
Gln-1062 is administered intranasally to prevent cleavage
to galantamine in the acidic environment of the stomach,
and in the presence of carboxy-esterases known to be ex-
pressed in the intestines and the liver. In female Wistar
rats, intravenous administration of 5.0-mg/kg Gln-1062 led
to a maximum concentration (Cmax) of 650 ng/mL in blood
with an AUClast of 528 ng h/mL and a Cmax of 13,627 ng/mg
in the brain with an AUClast of 9717 ng h/g. The brain-to-
blood AUC ratio of Gln-1062 was, therefore, 18.40. After
intranasal administration of 5.0 mg/kg, this ratio was 8.1
and intranasal administration of 20.0 mg/kg resulted in a ra-
tio of 10.2 (Supplementary Material).
Owing to its more favorable brain-to-blood ratio, Gln-
1062 is expected to have fewer peripheral side effects than
galantamine and other ChEIs and a comparable, or possibly
an improved, effectiveness in cognition enhancement. In this
study, safety, pharmacokinetic, and pharmacodynamic ef-
fects of Gln-1062 were assessed and compared with orally
administered galantamine and donepezil in healthy young
and elderly male subjects.2. Methods
2.1. Trial design and subjects
This was a double-blind, double dummy, double compar-
ator, and placebo controlled, sequential cohort single
ascending dose study (i.e., each subject received Gln-1062
nasal spray or placebo and capsules of either dummy or
active substance for both comparator drugs). Five dose levels
of intranasal Gln-1062, one dose level of oral galantamine,
and one dose level of oral donepezil were tested in healthy,
nonsmoking, male subjects. Main exclusion criteria were a
mini-mental state examination of 27 or lower, impaired renal
or liver function, use of interfering concomitant medication,
and intranasal abnormalities. The first two cohorts each con-
sisted of eight healthy young male subjects. In each cohort,
six subjects received a single dose of intranasal Gln-1062
5.5 mg (cohort 1) or 11 mg (cohort 2) and two subjectsFig. 1. Schematic overreceived placebo. The last three cohorts each consisted of
14 healthy elderly male subjects. In each cohort, six subjects
received a single dose of Gln-1062 22 mg (cohort 3), 33 mg
(cohort 4), or 44 mg (cohort 5). Oral galantamine 16 mg was
administered to 12 subjects in total (spread over cohorts 3
and 4) and oral donepezil 10 mg was administered to six sub-
jects (cohort 5). In each cohort, two subjects received double
placebo (six subjects in total; Fig. 1). In cohorts 3 and 4, all
drugs were administered at the same time. In cohort 5, done-
pezil or placebowas administered 3 hours before administra-
tion of Gln-1062 or placebo to have the expected time of
maximum concentration (Tmax) at approximately 3–4 hours
after dosing at the same time point as the Tmax of Gln-1062,
which was expected to be approximately 0.5–1 hour after
dosing. All subjects gave written informed consent for
participation in the study. The study was approved by the
ethics committee of the Leiden University Hospital,
the Netherlands. The study was conducted according to the
Dutch Act on Medical Research Involving Human Subjects
(WMO) and in compliance with Good Clinical Practice
(ICH-GCP) and the Declaration of Helsinki. The trial was
registered in the European Union Clinical Trials Register
(2013-004354-25).
2.2. Dosing rationale2.2.1. Gln-1062
In a 28-day intranasal toxicity study in Wistar rats, a
NOAEL for intranasal Gln-1062 was observed at a dose
level of 5 mg/kg. The human equivalent dose was estimated
to be 48 mg. With a 10-fold safety margin, a starting dose of
5.5 mg was chosen.
2.2.2. Galantamine
The recommended starting regimen for galantamine
(slow release formulation) in patients with AD is a titration
period of 4 weeks on 8 mg daily after which the dose can be
increased to 16 mg daily, and, if necessary, to 24 mg daily. In
previous clinical trials, immediate release formulations
without preceding dose titration have been given to healthy
subjects as a single dose up to 15 mg [14,15]. Three of eight
subjects not pretreated with a peripheral anticholinergic drug
as antidote experienced nausea at a dose of 15mg, and one of
eight patients vomited. Because the main advantage of Gln-
1062 would be a reduction of side effects, we chose to give a
single oral dose of galantamine 16 mg.view of cohorts.
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The recommended starting dose for donepezil (tablet
formulation) is 5 mg/d and is administered as a single daily
dose, usually in the morning. The dose can be increased to
10 mg/d as needed. Donepezil 10 mg was chosen because
it was the highest dose that was previously given as a single
oral dose to healthy subjects without titration [16].2.3. Pharmacokinetic assessment
Venous blood samples were obtained via an indwelling
catheter before administration of Gln-1062 or galantamine
or placebo and at 15 minutes, 30 minutes, 1 hour, 1 hour
30 minutes, 2 hours, 2 hours 30 minutes, 3 hours, 3 hours
30 minutes, 4 hours, 5 hours, 7 hours, 10 hours, and 23
hours after administration. In cohorts 4 and 5, the sample
at 7 hours after drug administration was replaced by samples
at 6 hours and 8 hours and an extra sample at 30 hours after
drug administration was added. Plasma concentrations of
Gln-1062 and galantamine were determined at WIL
Research Europe (Den Bosch, the Netherlands) by a vali-
dated method using high performance liquid chromatog-
raphy coupled to tandem-mass spectrometry.2.4. Pharmacodynamic assessments
The “NeuroCart” is a battery of sensitive tests for a wide
range of central nervous system (CNS) domains that was
developed to examine different kinds of CNS-active drugs.
The N-back test was used to evaluate working memory
[17–19], the Stroop test evaluated inhibition, interference,
and controlled versus automatic processing [20], adaptive
tracking measured attention and eye-hand coordination
[21–26], the visual analogue scale according to Bond and
Lader was used to assess subjective states [27,28],
pharmaco-electroencephalography, eye movements, and pu-
pil size were used to monitor any drug effects, which can be
interpreted as evidence of penetration and activity in the
brain [24,26,29–31], body movements were measured with
the body sway meter [32], the face encoding and recognition
task evaluated visual memory [33], and the visual verbal
learning test (VVLT) measured the whole scope of learning
behavior (i.e., acquisition, consolidation, storage and
retrieval) [34].
All tests with this device were performed twice at base-
line and repeated at 1 hour, 2 hours, 3 hours, 4 hours, 5
hours, 6 hours, 8 hours, and 10 hours after administration
of Gln-1062 or galantamine or placebo. In cohort 5, an
additional measurement was performed 2 hours after
administration of donepezil or placebo (i.e., 1 hour before
administration of Gln-1062 or placebo). The only excep-
tions were VVLT, which was only performed 1 hour 30 mi-
nutes after dosing of Gln-1062 or placebo, and face
recognition, which was performed before the dose and 1
hour 45 minutes after administration of Gln-1062 or pla-
cebo. Measurements were performed in a quiet roomwith ambient illumination with only one subject per ses-
sion in the same room.2.5. Safety assessments
All subjects underwent medical screening, including
medical history, physical examination, nasal examination,
vital signs measurement in supine and standing position,
12-lead electrocardiogram (ECG), urinalysis, drug screen,
and safety chemistry and hematology blood sampling. Dur-
ing study periods, safety was assessed using monitoring of
adverse events (AEs), nasal examination, vital signs, ECG,
and safety chemistry and hematology blood sampling.2.6. Statistics
All pharmacodynamic end points are summarized (mean
and standard deviation of the mean, median, and minimum
and maximum values) by treatment and time. To establish
whether significant treatment effects could be detected,
repeatedly measured variables were analyzed with a mixed
model analysis of variance with treatment, time and treat-
ment by time as fixed factors, and subject as random factor
and the (average) baseline measurement as covariate [35].
Single measured variables were analyzed by a mixed model
analysis of variance with fixed factor treatment. The young
subjects receiving active treatment were compared with
the young subjects on placebo and the elderly subjects on
active treatment were compared with the elderly on placebo.3. Results
3.1. Subjects
The study was conducted between November 2013 and
April 2014. A total of 16 healthy young and 42 healthy
elderly male subjects participated in this study. The healthy
young males had a mean age of 42.9 years (range 19–62), a
mean body weight of 77.6 kg (range 58.4–92.9), and a mean
body mass index (BMI) of 24.2 kg/m2 (range 18.7–28.6).
The healthy elderly males had a mean age of 71.2 years
(range 66–89), a mean body weight of 81.8 kg (range
62.6–121.5), and a mean BMI of 25.9 kg/m2 (range 20.4–
32.4). There were no dropouts after drug administration.3.2. Pharmacokinetics
After administration of Gln-1062, concentrations of
Gln-1062 and galantamine were measured. Based on the
noncompartmental pharmacokinetic analysis of the plasma
Gln-1062 concentrations, a dose-dependent increase in
exposure was observed up to a dose of 33 mg (Table 1,
Fig. 2). The 44-mg Gln-1062 dose led to a mean exposure
that was comparable with the 33-mg dose; however, in
view of the considerable interindividual variability in expo-
sure, the number of subjects per dose level (n 5 6) and the
limited increase in dose from 33 mg to 44 mg (133%), it
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A.C. Baakman et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 2 (2016) 13-2216cannot be concluded from these data that a dose-dependent
increase in exposure is not present beyond a dose of
33 mg. In general, subjects with a relatively high Cmax for
Gln-1062 also had a relatively high Cmax for Gln-1062–
derived galantamine. The Tmax Gln-1062 was 15–45
minutes, whereas the Tmax for galantamine after adminis-
tration of Gln-1062 was 2–4.5 hours. The half-life of
Gln-1062 increased with the administered dose form 1.07
to 2.08 hours. For galantamine derived from Gln-1062, the
half-life was approximately 10 hours for all dose levels.3.3. Safety
On each treatment, at least 50% of the subjects experi-
enced one or more treatment emergent AE (Table 2). Nasal
symptoms, such as nasal discomfort, rhinorrhea, and sneez-
ing, were reported most frequently and exclusively in the
Gln-1062 dosing groups, except for one case of nasal
discomfort in the donepezil group. Nasal symptoms sub-
sided in most cases within half an hour (data not presented).
No clear dose relationship was observed. Cholinergic symp-
toms (e.g., nausea, vomiting, diarrhea and hyperhidrosis)
were reported on all treatments, except for Gln-1062
5.5 mg and placebo. After administration of Gln-1062 11
and 22 mg, one subject in each cohort (16.7%) experienced
nausea. Gln-1062 at the highest dose levels led to nausea in
50% of subjects (n 5 3), which was higher than the inci-
dence of nausea in the galantamine 16 mg group (33.3%,
n 5 4) and in the donepezil 10 mg group (16.7%, n 5 1).
Although 33 mg of Gln-1062 led to a higher incidence of
nausea compared with galantamine, the severity, measured
with the VAS nausea, was on average lower for Gln-1062
33 mg (Fig. 3). The results on VAS nausea also indicated a
difference in time profile. The peak of nausea occurred 2
hours after administration of galantamine, versus 4 hours af-
ter administration of Gln-1062.
Vomiting did not occur after administration of Gln-1062
5.5 mg in healthy young subjects or after administration of
22 mg in healthy elderly subjects. Gln-1062 11 mg led to
vomiting in one healthy young subject (16.7%). Gln-1062
33 and 44 mg led to vomiting in two subjects in each cohort
(33.3%), which was lower than the incidence of vomiting af-
ter administration of galantamine 16 mg, which led to vom-
iting in five of 12 subjects (42%). After administration of
donepezil 10 mg, one subject (16.7%) vomited. One subject
(10%) who was administered placebo vomited. Diarrhea did
not occur after administration of Gln-1062 5.5 or 11 mg in
healthy young subjects, and administration of Gln-1062
22, 33 mg, and 44 mg in healthy elderly subjects led to diar-
rhea in one subject (16.7%) in each cohort. This incidence
was higher than after administration of galantamine 16 mg
(8.3%, n5 1) but lower than after administration of donepe-
zil 10 mg (33.3%, n 5 2).
Cold sweat or hyperhidrosis was seen in one subject
(16.7%) on Gln-1062 11 mg, three subjects (50%) on Gln-
1062 44 mg, and four subjects (33.3%) on galantamine.
SD error bars 22 mg: Gal 33 mg: Gal 44 mg: Gal
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Fig. 2. Plasma concentrations of Gln-1062 and galantamine in cohort 3–5. Abbreviations: Mem, Gln-1062; Gal, galantamine; SD, standard deviation.
A.C. Baakman et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 2 (2016) 13-22 17Headache was frequently reported in all dose groups. All
AEs were self-limiting, and most AEs were mild in intensity,
except for moderate nausea in one subject on 44 mg of Gln-
1062, one subject on galantamine and one subject on done-
pezil, one subject with moderate vomiting on placebo, and
two subjects with moderate postural dizziness on galant-
amine. No severe AEs occurred.
On nasal examination, three subjects in the Gln-1062 44-
mg group had dry white plaques in the nostrils, which were
not seen at the follow-up visit approximately 1 week after
dosing. Of these subjects, one had red and irritated nasal mu-
cosa at follow-up. One subject in the donepezil group had
red and irritated nasal mucosa at follow-up, whereas no nasal
abnormalities were seen during the day of drug administra-
tion. There were no clinically relevant abnormalities in vital
signs, ECG, or chemistry and hematology values in any of
the subjects.3.4. Pharmacodynamics
Pharmacodynamic effects of Gln-1062 compared with
placebo are summarized in Table 3. An improvement onTable 2
Most frequent occurring treatment emerging adverse events
Event
Gln-1062
5.5 mg
Gln-1062
11 mg
Gln-1062
22 mg
Any event 6 (100) 6 (100) 5 (83.3)
Nasal discomfort 6 (100) 6 (100) 4 (66.7)
Rhinorrhea 2 (33.3) 4 (66.7) 2 (33.3)
Sneezing 1 (16.7) 1 (16.7) 1 (16.7)
Nausea — 1 (16.7) 1 (16.7)
Vomiting — 1 (16.7) —
Diarrhea — — 1 (16.7)
Cold sweat or hyperhidrosis — 1 (16.7) —
Headache 2 (33.3) 2 (33.3) 3 (50)
NOTE. Number of subjects, percentage in parentheses.the adaptive tracking performance was seen in the
healthy young subjects receiving Gln-1062 11 mg and
healthy elderly subjects receiving Gln-1062 33 or
44 mg (Fig. 4).
On the VVLT, an improved immediate recall of the
words was seen for all doses of Gln-1062 in both young
and elderly subjects, when compared with galantamine.
In the healthy young subjects, the delayed word recall
also improved for both the 5.5- and the 11-mg dose level.
Word recognition did not improve on any of the Gln-1062
dose levels.
Pharmaco-EEG, face encoding and recognition test,
pupil-to-iris ratio, eye movements, the VAS mood and calm-
ness composite scores, the N-back test, body sway, and
Stroop color-word interference test did not show consistent
differences compared with placebo for any of the Gln-
1062 dose levels.
Administration of galantamine 16 mg did not induce any
measurable pharmacodynamic effects compared with pla-
cebo. Administration of donepezil 10 mg only led to an
improvement in adaptive tracking. The maximum effect on
the adaptive tracker test performance of Gln-1062 33 andGln-1062
33 mg
Gln-1062
44 mg
Galantamine
16 mg
Donepezil
10 mg Placebo
5 (83.3) 5 (83.3) 10 (83.3) 3 (50) 5 (50)
4 (66.7) 3 (50) — 1 (16.7) —
1 (16.7) 3 (50) — — —
1 (16.7) 3 (50) — — —
3 (50) 3 (50) 4 (33.3) 1 (16.7) —
2 (33.3) 2 (33.3) 5 (41.7) 1 (16.7) 1 (10)
1 (16.7) 1 (16.7) 1 (8.3) 2 (33.3) —
— 3 (50) 4 (33.3) — —
2 (33.3) — 1 (8.3) 2 (33.3) 3 (30)
95% CI error bars Placebo Mem_22 mg Mem_33 mg
Mem_44 mg Gal_16mg DPZ_10mg
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Fig. 3. Scores on VAS nausea in cohort 3–5. Abbreviations: VAS, visual analogue scale; Mem, Gln-1062; Gal, galantamine; DPZ, donepezil; CI, confidence
interval.
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zil 10 mg.4. Discussion
In this study, we examined the pharmacokinetics, side-
effect profile, and pharmacodynamic effects of Gln-1062
and compared these to the pharmacodynamics effects and
side-effect profile of galantamine and donepezil in healthy
male subjects.
Gln-1062 was rapidly absorbed into the systemic cir-
culation with a Cmax in plasma reached after approxi-
mately 15–45 minutes and a half-life of 1.1–2.8 hours,
depending on the dose administered. The Tmax of galant-
amine after administration of Gln-1062 was 2.3–4.7 hours
in all except the third cohort, which is approximately two
half-lives of Gln-1062. This would be consistent with the
hypothesis that Gln-1062 rapidly enters the brain, where
it may be cleaved into active galantamine. It is estab-
lished that the approved ChEIs all distribute into the
brain according to their lipophilicity. The lipophilic na-
ture of Gln-1062 and the avoidance of the first-pass effect
due to the intranasal administration could increase the
concentrations of Gln-1062 in the brain. A direct route
from the nose to the brain has never been demonstrated
in humans [36].
As a prodrug of galantamine, a low exposure of Gln-1062
generally resulted in a low formation of galantamine in most
subjects. However, some individuals seemed to reach lower
galantamine concentration than expected based on theirmeasured Gln-1062 exposure. This may be indicative of dif-
ferences between subjects in the rate of conversion of Gln-
1062 to galantamine.
All doses of Gln-1062 were safe and reasonably well
tolerated. The most frequently reported AEs were related
to irritation of nasal mucosa to which Gln-1062 is disposi-
tioned after intranasal administration. The reported irritation
was rapidly reversible and will be further studied in the next
clinical trial. The subjects generally considered the intra-
nasal administration to be easy and well tolerable and
compared it with the use of a nasal spray as is used in case
of a common cold.
As Gln-1062 is expected to have fewer peripheral side ef-
fects than galantamine and other ChEIs, the comparison of
AE’s between the different treatments was an important
aspect of this study. After administration of galantamine
16 mg, the most frequently reported treatment emergent
AEs were nausea, vomiting, and cold sweat or hyperhidrosis,
which is consistent with previous studies [37,38]. Gln-1062
22 mg has the same molarity as the 16 mg dose of galant-
amine, and based on preclinical studies, Gln-1062 22 mg
is expected to lead to at least 10-fold higher galantamine
concentrations in the brain compared with orally adminis-
tered galantamine 16 mg. At this dose of Gln-1062, nausea
occurred in 16.7% of subjects, compared with 33.3% in
the galantamine subjects, and vomiting did not occur at
all, although this was present in 41.7% of subjects on galant-
amine. The Gln-1062 33 mg dose led to a higher incidence
of nausea, compared with galantamine, but a lower severity
of nausea, as measured using a VAS for nausea. After
Table 3
Pharmacodynamic effects compared with placebo
Test parameter Cohort 1: Gln-1062 5.5 mg Cohort 2: Gln-1062 11 mg Cohort 3: Gln-1062 22 mg Cohort 4: Gln-1062 33 mg Cohort 5: Gln-1062 44 mg
Adaptive tracking (%) 1.96 (20.88 to 4.80)
P 5 .1581
3.47 (0.52 to 6.42)
P 5 .0247
0.64 (21.06 to 2.35)
P 5 .4474
1.79 (0.07 to 3.52)
P 5 .0424
0.74 (20.99 to 2.48)
P 5 .3887
VVLT: immediate word recall trial 1 3.42 (20.73 to 7.56)
P 5 .0984
3.92 (20.23 to 8.06)
P 5 .0621
2.67 (0.17 to 5.16)
P 5 .0367
1.97 (20.65 to 4.58)
P 5 .1355
2.57 (20.05 to 5.18)
P 5 .0541
VVLT: immediate word recall trial 2 3.17 (21.93 to 8.26)
P 5 .2025
1.83 (23.26 to 6.93)
P 5 .4510
3.50 (0.33 to 6.67)
P 5 .0315
1.77 (21.56 to 5.09)
P 5 .2880
1.77 (21.56 to 5.09)
P 5 .2880
VVLT: immediate word recall trial 3 5.00 (20.58 to 10.58)
P 5 .0749
3.00 (22.58 to 8.58)
P 5 .2662
0.67 (23.23 to 4.56)
P 5 .7302
0.60 (23.49 to 4.69)
P 5 .7672
1.00 (23.09 to 5.09)
P 5 .6222
VVLT: delayed word recall 3.42 (22.62 to 9.45)
P 5 .2431
3.25 (22.79 to 9.29)
P 5 .2657
20.33 (23.58 to 2.91)
P 5 .8354
20.00 (23.63 to 3.63)
P 5 1.0000
21.00 (24.63 to 2.63)
P 5 .5780
VVLT: word recognition 20.15 (28.05 to 7.75)
P 5 .9674
1.45 (26.45 to 9.35)
P 5 .6939
0.87 (24.09 to 5.82)
P 5 .7231
20.67 (26.45 to 5.12)
P 5 .8153
2.17 (23.11 to 7.45)
P 5 .4083
N-back, 0-back (correct-incorrect/total) 0.04 (20.02 to 0.10)
P 5 .1696
0.03 (20.03 to 0.09)
P 5 .3145
0.02 (20.02 to 0.05)
P 5 .3729
0.03 (20.01 to 0.06)
P 5 .1690
0.03 (20.00 to 0.07)
P 5 .0654
N-back, 1-back (correct-incorrect/total) 20.00 (20.17 to 0.16)
P 5 .9835
20.05 (20.21 to 0.12)
P 5 .5597
0.02 (20.02 to 0.06)
P 5 .3402
20.03 (20.07 to 0.02)
P 5 .2212
20.01 (20.06 to 0.03)
P 5 .5016
N-back, 2-back (correct-incorrect/total) 0.09 (20.06 to 0.25)
P 5 .2199
0.13 (20.02 to 0.28)
P 5 .0867
20.02 (20.09 to 0.06)
P 5 .6835
20.02 (20.10 to 0.06)
P 5 .5957
0.02 (20.05 to 0.10)
P 5 .5430
Face recognition number correct 20.77 (24.17 to 2.64)
P 5 .6332
4.54 (1.22 to 7.87)
P 5 .0116
22.58 (27.22 to 2.06)
P 5 .2642
20.54 (.5.15 to 4.08)
P 5 .8135
21.63 (26.30 to 3.05)
P 5 .4822
Stroop (correct congruent – correct incongruent) 20.39 (20.94 to 0.15)
P 5 .1411
20.60 (21.21 to 0.01)
P 5 .0535
0.10 (21.05 to 1.25)
P 5 .8606
0.58 (20.52 to 1.68)
P 5 .2909
0.11 (20.98 to 1.20)
P 5 .8406
EEG alpha Fz-Cz (uV) 213.2% (230.5% to 8.5%)
P 5 .1914
20.8% (219.5% to 22.1%)
P 5 .9310
7.8% (27.0% to 25.1%)
P 5 .3088
21.5% (4.8% to 40.8%)
P 5 .0116
210.1% (224.2% to 6.6%)
P 5 .2121
EEG alpha Pz-Oz (uV) 28.9% (223.8% to 8.9%)
P 5 .2782
213.1% (227.2% to 3.7%)
P 5 .1086
13.8% (25.4% to 36.9%)
P 5 .1633
19.7% (20.2% to 43.6%)
P 5 .0530
2.1% (216.3% to 24.5%)
P 5 .8306
Saccadic peak velocity (/s) 9.90 (217.50 to 37.30)
P 5 .4465
8.32 (218.32 to 34.95)
P 5 .5097
26.92 (4.11 to 49.73)
P 5 .0223
0.92 (221.84 to 23.68)
P 5 .9349
19.19 (25.54 to 43.92)
P 5 .1242
Saccadic inaccuracy (%) 21.56 (22.77 to 20.35)
P 5 .0157
21.78 (23.03 to 20.54)
P 5 .0088
0.24 (21.01 to 1.48)
P 5 .7005
0.08 (21.14 to 1.30)
P 5 .8970
20.22 (21.57 to 1.12)
P 5 .7363
Abbreviations: VVLT, visual verbal learning test; EEG, electroencephalogram.
NOTE. Mean, confidence interval in parentheses.
A
.C
.
B
a
a
km
a
n
et
a
l.
/
A
lzh
eim
er’s
&
D
em
en
tia
:
T
ra
n
sla
tio
n
a
l
R
esea
rch
&
C
lin
ica
l
In
terven
tio
n
s
2
(2
0
1
6
)
1
3
-2
2
1
9
95% CI error bars Placebo Mem_22 mg Mem_33 mg
Mem_44 mg Gal_16mg DPZ_10mg
egnahc
:)
%(
gnikcart
e vitpa d
A
-4
-2
0
2
4
6
Time (hh:mm)
0:00 1:00 2:00 3:00 4:00 5:00 6:00 7:00 8:00 9:00 10:00 11:00
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severity of nausea were higher, compared with galantamine
16 mg. Compared to donepezil, Gln-1062 33 and 44 mg both
had a higher incidence of nausea and vomiting but a lower
incidence of diarrhea. It can be concluded that single doses
of Gln-1062 up to 33 mg seem to be tolerated at least as
well as a single dose of galantamine 16 mg but are likely
to lead to substantially higher galantamine concentrations
in the brain in comparison with an oral dose of 16-mg galant-
amine. The single dose design of the study is a limitation
with respect to the extrapolation of the results to clinical
practice because the treatment of symptoms of AD with
one of the registered ChEIs will always imply daily dosing
with a period of uptitration. The results of this study provide
a good base for a multiple dose study to investigate this in
more detail. Another way to reduce side effects with classic
ChEIs is transdermal administration, which, at this stage, is
only possible with rivastigmine. However, this does not alter
the ratio of peripheral and central cholinesterase inhibition,
although the preclinical data of Gln-1062 and the results of
the presented study suggest that this ratio might be more
favorable for Gln-1062 compared with the currently regis-
tered ChEIs.
The analysis of pharmacodynamic effects in this study
was exploratory in nature because the study was not powered
to detect differences between treatments and there was no
correction for multiple testing. This needs to be taken into
account when interpreting the pharmacodynamic results.
Previous research has shown that acetylcholine plays an
important role in attentional processes and memory andChEIs also primarily affect these domains in patients with
AD [38,39]. This is in line with the findings in our study,
where administration of Gln-1062 led to consistent improve-
ments on adaptive tracking, which is very sensitive to com-
pounds that affect vigilance and arousal, and VVLT, a test of
verbal memory. The improvements on the VVLT after
administration of Gln-1062 in healthy elderly subjects
were observed on the immediate recall trials, suggesting
an effect on short-term memory capacity or learning, but
not on retrieval of previously stored information, which
would be consistent with previous research [39–42]. The
lack of effect of donepezil on VVLT might be explained
by the fact that donepezil does not have a direct effect on
nicotinic acetylcholine receptors, which galantamine also
has [43]. Galantamine allosterically sensitizes neuronal
nicotinic acetylcholine receptors, but when orally applied
has limited brain penetration, which may explain the lack
of acutely measurable pharmacodynamic effects of oral gal-
antamine.
The time profiles of the adaptive tracking test in the
healthy elderly subjects showed that the administration of
Gln-1062 resulted in larger effects compared with oral
administration of 16-mg galantamine and placebo mainly
due to an improvement that occurred in the first hours after
study drug administration. After approximately 4 hours, the
adaptive tracker test curves of the Gln-1062 33 and 44 mg
cohorts return to the same level as the galantamine 16-mg
curve and continue to run in parallel. This is in line with
the hypothesis that Gln-1062, as a prodrug of galantamine,
enters the CNS to a greater extent than (oral) galantamine
A.C. Baakman et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 2 (2016) 13-22 21in the initial hours after drug administration. The distribu-
tion of small molecules such as Gln-1062 and galantamine
via the blood-brain barrier is extremely fast. It is the higher
level of galantamine that is produced in the brain after
enzymatic cleavage of Gln-1062 that causes the higher
level of activation of nicotinic receptors and, thus, the
higher pharmacodynamics effects compared with oral gal-
antamine. Several hours after the dose (64 hours), Gln-
1062 can be expected to be almost completely converted
into galantamine, which is likely to be the reason why
the Gln-1062 33 and 44 mg curves are no longer distin-
guishable from the galantamine 16-mg curve at 4 hours
and beyond. Establishment of a pharmacokinetic-
pharmacodynamic model may shed more light on the exact
relationship between the pharmacodynamics effects
observed and the estimated brain concentrations and
measured plasma concentrations of Gln-1062 and galant-
amine. Donepezil showed an improvement in adaptive
tracking performance that was similar in magnitude to
Gln-1062 33 and 44 mg. However, the donepezil-induced
improvement lasted considerably longer. This is consistent
with the pharmacokinetic profile of donepezil and its half-
life of 70 hours.
In conclusion, this study demonstrates that Gln-1062
is safe and well tolerated at single dose levels up to
33 mg. The pharmacokinetic and pharmacodynamic pro-
file of Gln-1062 as observed in this study are in accor-
dance with the hypothesis that Gln-1062 enters the
CNS very rapidly and is then enzymatically cleaved to
the active ingredient galantamine, resulting in higher
CNS concentrations than can be achieved by oral admin-
istration of galantamine. The observation that, in this
study, the dose of 22 mg of Gln-1062 induces fewer
cholinergic side effects than 16 mg of galantamine,
which has the same molarity, supports this hypothesis.
Based on these observations, Gln-1062 is expected to
be better tolerated and to be more effective than oral gal-
antamine in treating the symptoms of patients with AD
and may be a promising compound for an improved
symptomatic treatment.Acknowledgments
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1. Systematic review: The authors searched PubMed
for publications regarding the effectiveness and
side effects of cholinesterase inhibitors (ChEIs) in
patients with Alzheimer’s disease (AD).
2. Interpretation: ChEIs can reduce symptoms in pa-
tients with mild-to-moderate AD. Even the daily
recommended doses induce side effects that lead to
discontinuation of medication. The effects of the
newly developed prodrug of galantamine have not
been investigated before in humans.
3. Future directions: This study provides a good basis
for a head-to-head comparison of Memogain and
galantamine in patients with AD. In such a study, the
long-term safety and efficacy in patients with AD
will be determined. Preclinical evidence suggests
that in addition to providing a better benefit-risk ratio
in symptomatic relief than current drugs, Memogain
may lead to disease modification.References
[1] Mikulca JA, NguyenV, Gajdosik DA, Teklu SG, Giunta EA, Lessa EA,
et al. Potential novel targets for Alzheimer pharmacotherapy: II. Up-
date on secretase inhibitors and related approaches. J Clin Pharm
Ther 2014;39:25–37.
[2] Prins ND, Visser PJ, Scheltens P. Can novel therapeutics halt the am-
yloid cascade? Alzheimers Res Ther 2010;2:5.
[3] Prins ND, Scheltens P. Treating Alzheimer’s disease with monoclonal
antibodies: Current status and outlook for the future. Alzheimers Res
Ther 2013;5:56.
[4] Patel KR. Biogen’s aducanumab raises hope that Alzheimer’s can be
treated at its source. Manag Care 2015;24:19.
[5] Siemers ER, Sundell KL, Carlson C, Case M, Sethuraman G, Liu-
Seifert H, et al. Phase 3 solanezumab trials: Secondary outcomes in
mild Alzheimer’s disease patients. Alzheimers Dement 2016;
12:110–20.
[6] Wallin AK, Wattmo C, Minthon L. Galantamine treatment in Alz-
heimer’s disease: Response and long-term outcome in a routine clin-
ical setting. Neuropsychiatr Dis Treat 2011;7:565–76.
[7] Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane
Database Syst Rev 2006;CD005593.
[8] Birks J, Grimley EJ, Iakovidou V, Tsolaki M, Holt FE. Rivastigmine
for Alzheimer’s disease. Cochrane Database Syst Rev 2009;
CD001191.
[9] Olin J, Schneider L. Galantamine for Alzheimer’s disease. Cochrane
Database Syst Rev 2002;CD001747.
[10] Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P,
et al. Efficacy and safety of rivastigmine in patients with Alzheimer’s
disease: International randomised controlled trial. BMJ 1999;
318:633–8.
[11] Tariot PN, SolomonPR,Morris JC,KershawP,Lilienfeld S,DingC.A5-
month, randomized, placebo-controlled trial of galantamine in AD. The
Galantamine USA-10 Study Group. Neurology 2000;54:2269–76.
A.C. Baakman et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 2 (2016) 13-2222[12] Knopman DS. Donepezil 23 mg: An empty suit. Neurol Clin Pract
2012;2:352–5.
[13] Loy C, Schneider L. Galantamine for Alzheimer’s disease and mild
cognitive impairment. Cochrane Database Syst Rev 2006;CD001747.
[14] Riemann D, Gann H, Dressing H, MullerWE, Aldenhoff JB. Influence
of the cholinesterase inhibitor galantamine hydrobromide on normal
sleep. Psychiatry Res 1994;51:253–67.
[15] ZhaoQ,BrettM,VanON,HuangF,RaoultA,VanPA, et al.Galantamine
pharmacokinetics, safety, and tolerability profiles are similar in healthy
Caucasian and Japanese subjects. J Clin Pharmacol 2002;42:1002–10.
[16] Mihara M, Ohnishi A, Tomono Y, Hasegawa J, Shimamura Y,
Yamazaki K, et al. Pharmacokinetics of E2020, a new compound for
Alzheimer’s disease, in healthy male volunteers. Int J Clin Pharmacol
Ther Toxicol 1993;31:223–9.
[17] LimHK, Juh R, Pae CU, Lee BT, Yoo SS, Ryu SH, et al. Altered verbal
working memory process in patients with Alzheimer’s disease: An
fMRI investigation. Neuropsychobiology 2008;57:181–7.
[18] Rombouts SA, Barkhof F, Van Meel CS, Scheltens P. Alterations in
brain activation during cholinergic enhancement with rivastigmine in
Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2002;73:665–71.
[19] Sweet LH, Rao SM, Primeau M, Durgerian S, Cohen RA. Functional
magnetic resonance imaging response to increased verbal working
memory demands among patients with multiple sclerosis. Hum Brain
Mapp 2006;27:28–36.
[20] Laeng B, Lag T, Brennen T. Reduced Stroop interference for opponent
colors may be due to input factors: Evidence from individual differ-
ences and a neural network simulation. J Exp Psychol Hum Percept
Perform 2005;31:438–52.
[21] Borland RG, Nicholson AN. Comparison of the residual effects of two
benzodiazepines (nitrazepam and flurazepam hydrochloride) and
pentobarbitone sodium on human performance. Br J Clin Pharmacol
1975;2:9–17.
[22] Borland RG, Nicholson AN. Visual motor co-ordination and dynamic
visual acuity. Br J Clin Pharmacol 1984;18 Suppl 1:69S–72.
[23] Gijsman HJ, van Gerven JM, Tieleman MC, Schoemaker RC,
Pieters MS, Ferrari MD, et al. Pharmacokinetic and pharmacodynamic
profile of oral and intravenous meta-chlorophenylpiperazine in healthy
volunteers. J Clin Psychopharmacol 1998;18:289–95.
[24] van Steveninck AL, Schoemaker HC, Pieters MS, Kroon R,
Breimer DD, Cohen AF. A comparison of the sensitivities of adaptive
tracking, eye movement analysis and visual analog lines to the effects
of incremental doses of temazepam in healthy volunteers. Clin Phar-
macol Ther 1991;50:172–80.
[25] van Steveninck AL, Gieschke R, Schoemaker HC, Pieters MS,
Kroon JM, Breimer DD, et al. Pharmacodynamic interactions of diaz-
epam and intravenous alcohol at pseudo steady state. Psychopharma-
cology (Berl) 1993;110:471–8.
[26] van Steveninck AL, van Berckel BN, Schoemaker RC, Breimer DD,
van Gerven JM, Cohen AF. The sensitivity of pharmacodynamic testsfor the central nervous system effects of drugs on the effects of sleep
deprivation. J Psychopharmacol 1999;13:10–7.
[27] de Visser SJ, van der Post JP, de Waal PP, Cornet F, Cohen AF,
van Gerven JM. Biomarkers for the effects of benzodiazepines in
healthy volunteers. Br J Clin Pharmacol 2003;55:39–50.
[28] Norris H. The action of sedatives on brain stem oculomotor systems in
man. Neuropharmacology 1971;10:181–91.
[29] Baloh RW, Sills AW, Kumley WE, Honrubia V. Quantitative measure-
ment of saccade amplitude, duration, and velocity. Neurology 1975;
25:1065–70.
[30] Bittencourt PR, Wade P, Smith AT, Richens A. Benzodiazepines
impair smooth pursuit eye movements. Br J Clin Pharmacol 1983;
15:259–62.
[31] van Steveninck AL. A microcomputer based system for recording and
analysis of smooth pursuit and saccadic eye movements. Br J Clin
Pharmacol 1989;27:712P–3.
[32] Wright BM. A simple mechanical ataxia-meter. J Physiol 1971;218
Suppl:27P–8.
[33] Lezak MD, Howieson DB, Loring DW. Neuropsychological assess-
ment. 4th ed. New York: Oxford University Press; 2004.
[34] de Haas SL, Franson KL, Schmitt JA, Cohen AF, Fau JB, Dubruc C,
et al. The pharmacokinetic and pharmacodynamic effects of
SL65.1498, a GABA-A alpha2,3 selective agonist, in comparison
with lorazepam in healthy volunteers. J Psychopharmacol 2009;
23:625–32.
[35] Moser EB. Repeated measures modeling with PROC MIXED. SUGI
29. P188–29. 2004. Ref Type: Conference Proceeding.
[36] Merkus P, Guchelaar HJ, Bosch DA, Merkus FW. Direct access of
drugs to the human brain after intranasal drug administration?
Neurology 2003;60:1669–71.
[37] Farlow MR. Clinical pharmacokinetics of galantamine. Clin Pharma-
cokinet 2003;42:1383–92.
[38] Repantis D, Laisney O, Heuser I. Acetylcholinesterase inhibitors and
memantine for neuroenhancement in healthy individuals: A systematic
review. Pharmacol Res 2010;61:473–81.
[39] PepeuG, GiovanniniMG, Bracco L. Effect of cholinesterase inhibitors
on attention. Chem Biol Interact 2013;203:361–4.
[40] Drachman DA, Leavitt J. Memory impairment in the aged: Storage
versus retrieval deficit. J Exp Psychol 1972;93:302–8.
[41] Drachman DA, Leavitt J. Human memory and the cholinergic system.
A relationship to aging? Arch Neurol 1974;30:113–21.
[42] Bracco L, Bessi V, Padiglioni S, Marini S, Pepeu G. Do cholines-
terase inhibitors act primarily on attention deficit? A naturalistic
study in Alzheimer’s disease patients. J Alzheimers Dis 2014;
40:737–42.
[43] Samochocki M, Hoffle A, Fehrenbacher A, Jostock R, Ludwig J,
Christner C, et al. Galantamine is an allosterically potentiating ligand
of neuronal nicotinic but not of muscarinic acetylcholine receptors. J
Pharmacol Exp Ther 2003;305:1024–36.
